The Filing Desk

10x Genomics

TXG · Nasdaq · Health Care · Financials, fiscal 2017 to 2025

TXG · Last close · November 13, 2026
$58.19
Value 10x Genomics yourself

10x Genomics' revenue rose 5.2% to $643 million in fiscal 2025. Its operating margin was −9.5%, up from −31.9% a year earlier. Free cash flow was $130 million. The diluted share count rose 3.6%.

10x Genomics, Inc. Latest fiscal year ended December 31, 2025 10-K filed February 13, 2026 · 0001628280-26-007822 Updated
Revenue
$643M
5.2%
Operating margin
−9.5%
22.4 pts
Net income
−$44M
 
Free cash flow
$130M
 
Return on capital
−16.3%
29.6 pts
Market cap
$7.6B
Nov 13 close
P/E
—
Loss: no P/E

Operating margin is operating income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on capital is after-tax operating income as a share of the money invested in the business: debt plus equity, minus cash. Market cap is the last closing share price times the latest diluted share count, so it is approximate. P/E is the last close divided by diluted earnings per share over the last four quarters, or the latest fiscal year where the quarters aren't available; there is none when the company made a loss.

About these figures. Interest coverage for fiscal 2025 is blank: the 10-K's structured data has no interest expense for that year.

Charts show fiscal years, from the 10-K filings.

What 10x Genomics does

This company sells instruments, chemical consumables and software that let scientists study biology one cell at a time and see where molecules sit inside tissue. Its customers are researchers at universities, medical research centers and drug companies. The company says its products have been used in more than 10,000 peer-reviewed articles.

It has two main product families. Its single cell portfolio, built on the Chromium platform, splits samples into tiny partitions, tags each with a barcode, and then reads them together on a sequencer, so researchers can measure many cells in parallel. Its spatial portfolio, built on the Visium and Xenium platforms, maps where biological molecules are in a tissue sample. It earns money from selling instruments and from the chips, reagents and other consumables customers must buy to run them.

Revenue was $642.8 million in 2025, up 5% from the year before. It reported a net loss in 2025 and in 2024.

Its biggest risks, as it describes them

  • Its quarterly and yearly results can swing widely and are hard to predict.
  • It faces intense competition, including rivals developing new technologies that could replace its products.
  • Price cuts or discounts could hurt its results if it does not gain offsetting benefits.
  • It may fail to develop new products or improved versions of existing ones.
  • Its demand depends on research spending by institutions, and a reduction would limit sales.
From 10x Genomics's annual report on Form 10-K, filed February 13, 2026, in our words; the 10-K has the full description and every risk factor. Updated with each new annual report.

Income statement

Revenue and net income
US$ billions, fiscal years; net losses in red. Revenue on the left axis, net income on the right; zero is the same line on both.
Revenue (left axis)Net income (right axis)
Gross profit, R&D and operating income
US$ billions, fiscal years. Gross profit is revenue minus the cost of what was sold; research and development is one of the costs paid from it; what remains after all operating costs is operating income. Losses in red.
Gross profitResearch and developmentOperating income
Margins
Percent of revenue
GrossOperatingNetFree cash flow

10x Genomics lost money in fiscal 2025: a net loss of $44 million.

Diluted earnings per share
US$ per share, fiscal years, restated for any stock splits; loss years in red.

Returns on capital

Return on capital and on equity
Percent. Return on capital is after-tax operating income over the money invested in the business (debt plus equity, minus cash); return on equity is net income over shareholders' equity. Both use the average of opening and closing balances.
Return on capitalReturn on equity

Balance sheet

Cash and debt
US$ billions, at each fiscal year end. Debt includes finance leases.
Cash and short-term investmentsDebt
Assets, liabilities and equity
US$ billions, at each fiscal year end. Assets equal liabilities plus equity; negative equity in red.
Total assetsTotal liabilitiesShareholders' equity
Debt and liquidity ratios
Times. Debt to equity, current assets over current liabilities, and net debt over EBITDA (a full year's).
Debt to equityCurrent ratioNet debt to EBITDA

Five years at a glance

Fiscal year endFY21FY22FY23FY24FY25
Cash and short-term investments587430389393523
Debt incl. finance leases00000
Net debt (negative means net cash)−587−430−389−393−523
Net debt to EBITDA—————
Debt to equity0.0x0.0x0.0x0.0x0.0x
Interest coverage−60.3x−352.8x−8,040.3x−48,639.8x—
Current ratio6.8x4.8x4.7x5.0x4.5x
Quick ratio6.2x4.2x4.1x4.3x4.1x
US$ millions unless stated, at each fiscal year end. Net debt to EBITDA is debt minus cash, divided by operating income before depreciation and amortization: roughly how many years of those earnings the net debt equals. Debt to equity is debt as a multiple of shareholders' equity. Interest coverage is operating income divided by interest expense. The current ratio is current assets over current liabilities; the quick ratio leaves out inventory.

Cash flow

Cash from operations, capital spending and free cash flow
US$ billions, fiscal years. Free cash flow is cash from operations minus capital spending; negative years in red.
Cash from operationsCapital spendingFree cash flow
Stock-based compensation and buybacks
US$ billions, fiscal years. Shares paid to employees (stock-based compensation, a cost that uses no cash) against cash spent buying shares back. Buybacks that only match it leave the share count roughly where it was.
Stock-based compensationShare buybacks
Dividends and buybacks
US$ billions, cash paid in each fiscal year
DividendsShare buybacks
Diluted share count
Weighted-average diluted shares, millions

Projections

Project 10x Genomics' revenue, net income and earnings per share five years ahead in a bull, a base and a bear case with your own figures, and see the share prices your P/E estimates give them, or value it with a discounted cash flow model. Every projected figure is yours: it is not a forecast of ours.

Insider trades

Over the 12 months between November 14, 2025 and November 13, 2026, no insider bought 10x Genomics shares on the open market, and 6 insiders sold $18.8 million, $9.6 million of it under trading plans set up in advance.

Buys and sells by month
US$ millions, open-market purchases (up) and sales (down) by officers, directors and 10% owners in each month.
BoughtSold
DateInsiderTradeSharesPriceValueFiling
Nov 10, 2026Serge SaxonovChief Executive Officer, DirectorSold31,000$62.90$1.9 millionForm 4
Sep 22, 2026Serge SaxonovChief Executive Officer, DirectorSold plan25,000$81.22$2.0 millionForm 4
Sep 22, 2026Shehnaaz SulimanDirectorSold plan5,723$81.19$464,677Form 4
Sep 9, 2026Adam TaichChief Financial OfficerSold plan46,388$64.58$3.0 millionForm 4
Sep 3, 2026John R StuelpnagelDirectorSold20,000$61.76$1.2 millionForm 4
Aug 26, 2026Serge SaxonovChief Executive Officer, DirectorSold plan10,486$63.70$667,913Form 4
Aug 24, 2026Serge SaxonovChief Executive Officer, DirectorSold18,545$63.02$1.2 millionForm 4
Aug 24, 2026Adam TaichChief Financial OfficerSold17,166$63.02$1.1 millionForm 4
Aug 24, 2026Benjamin J. HindsonSee Remarks, DirectorSold13,818$63.02$870,810Form 4
Aug 24, 2026Shehnaaz SulimanDirectorSold plan2,207$63.65$140,486Form 4
Aug 14, 2026Sarah A. TeichmannDirectorSold plan2,273$57.15$129,902Form 4
Aug 13, 2026Sarah A. TeichmannDirectorSold plan5,278$57.29$302,377Form 4
The latest 12 of 30 trades. Open-market purchases and sales by officers, directors and 10% owners, from their Form 4 filings with the SEC: one row per person, day and filing, at the day's average price. Grants, option exercises and shares withheld for tax aren't counted. Insiders buy and sell for many reasons, such as taxes, spreading their savings or a plan set up months earlier, so a trade on its own says little about where a company is heading. For information only, not investment advice. Insider trades at all companies

Indicators

Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.

IndicatorFY23FY24FY25
Piotroski F-score2 of 96 of 95 of 9
Rule of 409.5%−2.2%25.5%
Altman Z''0.470.281.63
Accruals ratio−24.1%−20.1%−18.3%
Piotroski F-score: how many of nine simple tests of profitability, funding and efficiency the company passed in the year (Piotroski, 2000); 8 or 9 is strong, 0 to 2 weak. Rule of 40: revenue growth plus free cash flow margin; software investors treat 40% or more as the bar. Altman Z'': working capital, retained earnings, operating income and equity weighed against assets and liabilities (Altman, 1995); Altman puts above 2.6 in the safe zone and below 1.1 in the distress zone. Accruals ratio: net income minus cash from operations, over average total assets; lower means profit is backed by cash.

The nine F-score tests

TestFY23FY24FY25
Net income is positiveFailFailFail
Cash from operations is positiveFailPassPass
Return on assets roseFailPassPass
Cash from operations exceeds net incomePassPassPass
Debt fell relative to assetsFailFailFail
Current ratio roseFailPassFail
Share count didn't riseFailFailFail
Gross margin roseFailPassPass
Revenue rose relative to assetsPassPassPass
F-score2 of 96 of 95 of 9
Companies that report no gross profit are scored on the other eight.

Compare

Put 10x Genomics side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.

Similar companies

CompanyYearRevenue growthOperating marginFree cash flow marginReturn on capitalNet debt to EBITDAF-scoreCompare
10x GenomicsFY255.2%−9.5%20.2%−16.3%—5
AzentaFY253.5%−4.5%6.5%———Compare
Bio-TechneFY26−0.4%20.7%21.7%9.2%−0.2x9Compare
Mesa LaboratoriesFY263.4%7.4%15.9%4.8%1.0x8Compare
Cytek BiosciencesFY250.5%−20.0%−4.3%———Compare
Each company's latest fiscal year. Fiscal years end in different months, so the periods don't line up exactly. Free cash flow margin is free cash flow as a share of revenue. Net debt to EBITDA is explained under the balance sheet, and the F-score under Indicators.

9 years of figures

Fiscal yearFY17FY18FY19FY20FY21FY22FY23FY24FY25
Income statement
Revenue71146246299490516619611643
Revenue growth—105.8%68.1%21.5%64.1%5.3%19.8%−1.3%5.2%
Gross profit60118185240416396409414444
Research and development324883123212266270265239
Operating income−18−111−31−534−52−168−265−195−61
Net income−19−112−31−543−58−166−255−183−44
Diluted EPS (US$)−1.62−8.40−0.80−5.37−0.53−1.46−2.18−1.52−0.35
Diluted shares (millions)121339101110114117120125
Cash flow
Cash from operations−11−7635−218−21−34−157136
Capital expenditure46433710113249126
Free cash flow−14−83−8−255−123−165−64−6130
Dividends paid000000000
Share buybacks000000000
Acquisitions000064000
Stock-based compensation23134996137167141109
Balance sheet at fiscal year end
Cash and short-term investments4865424664587430389393523
Debt incl. finance leases—3030000000
Total assets—1246069291,0191,0299659191,041
Total liabilities—101186190201223224208245
Shareholders' equity−112−220420739818806741710796
Margins and ratios
Gross margin85.1%80.4%75.2%80.4%84.9%76.7%66.2%67.9%69.0%
Operating margin−25.9%−75.7%−12.4%−178.7%−10.7%−32.5%−42.9%−31.9%−9.5%
Net margin−26.4%−76.9%−12.7%−181.6%−11.9%−32.1%−41.2%−29.9%−6.8%
Free cash flow margin−20.3%−56.5%−3.3%−85.2%−25.0%−32.0%−10.3%−0.9%20.2%
Rule of 40 (growth + FCF margin)—49.3%64.8%−63.6%39.1%−26.7%9.5%−2.2%25.5%
Return on capital————−27.0%−43.8%−57.6%−45.9%−16.3%
Return on equity——−31.2%−93.6%−7.5%−20.4%−33.0%−25.2%−5.8%
Return on assets——−8.6%−70.7%−6.0%−16.2%−25.6%−19.4%−4.4%
Net debt to EBITDA—————————
US$ millions unless stated. Where a later 10-K restated a year, the latest filed figure is shown. Download all figures (CSV, US$ millions)
Source: 10x Genomics' Form 10-K filings, from SEC EDGAR. For information only, not investment advice. The Filing Desk is not affiliated with 10x Genomics.